Next Thursday's event brings together four companies with different backgrounds that have one thing in common – huge potential.
Real Estate Investors (LON:RLE), Acal (LON:ACL), Midatech Pharma (LON:MTPH) & Constellation Healthcare Technologies (LON:CHT) are in great positions to capitalise on prevailing trends in their particular markets.
Make sure you don't miss out on June 4 and secure your place HERE.
Real Estate Investors is a Birmingham-based property company with a portfolio worth over £100 million. The current market capitalisation is £114 million.
Focused on retail, office and residential property, REI adds value through lettings, rent reviews, lease renewals, change of use and planning gains.
Management has over 100 years of combined property experience and has seen the company's market capitalisation rise to £115 million from £5 million since its involvement in 2007, representing an overall rise of 2,300%.
Chief Executive Officer Paul Bassi will be updating investors on the company's future plans for further growth.
Listed on the LSE and supplying around 20,000 industrial companies, Acal works across a wide range of technology areas including power and magnetics, communications and sensors and imaging & photonics.
Over the 2010 - 2014 period, sales impressively grew from £116 million to £212 million, while the business as a whole returned to growing profitability. The company's current market cap is £176 million.
The company's key markets lie in the UK, Germany & France, while the company has recently broken into the US and Slovakia via the acquisitions of Noratel and Foss.
CEO Nick Jefferies will be presenting at the forum to explain Acal's story in more detail.
Midatech Pharma is a nanomedicine company focused on the commercialisation of multiple, high value, targeted therapies for major diseases with unmet medical need.
The company - which has a market cap of £81 million - intends to build a long term, profitable entity which generates revenues through R&D collaborations, partner licensing and royalty deals & the commercialisation of its own products.
Jim Phillips, CEO, recently told investors that its eye-disease drug Opsisorin is on an accelerated programme in terms of investment priorities after it showed "exceedingly good promise" in recent testing.
Jim will be presenting at the event and updating investors on the company's future plans.
Meanwhile Constellation Healthcare Technologies is a healthcare services organisation which serves the physician market in the United States.
CHT has positioned itself to capitalise on an increasing trend of physicians in the US outsourcing their billing operations and management estimate that there is a $37 billion market which Constellation should be able to capture a chunk of.
Confidence in the company's ambitions was recently underlined by the fact that it raised $12.9 million to fund acquisitions and accelerate its growth plans.
CEO Paul Parma, who recently said he is hoping for a $250 million valuation next year, will be at the forum to outline the investment proposition.
Please join us at 5:45pm to allow for a prompt 6pm start. Each company has 20 minutes to give a short presentation and then 10 minutes Q&A. This will be followed by the 'Champagne Raffle' where six guests will win a bottle each.
The event will be rounded off with a drinks reception with canapés.